This site is intended for UK Healthcare professionals only

Are you a UK Healthcare professional?

We are unfortunately unable to allow patients to attend DPC

We invite people living with diabetes to join our United Through Diabetes event happening on World Diabetes Day!

Join our World Diabetes Day event?

DPC 2020 programme

IMAGE

Loading

Should SGLT2 inhibitors be part of standard of care for patients with insufficiently controlled type 2 diabetes?

11 Nov 2020
CVRM Theatre

Not all patients with type 2 diabetes are sufficiently controlled with first-line therapy and, with several different options for treatment intensification, it can be difficult to determine the best approach for our patients. Join our experts, Dr Sarah Davies and Professor Mike Cummings, to hear their thoughts on the role of SGLT2 inhibitors, such as Jardiance® (empagliflozin), as an option for improving glycaemic control, as well as the importance of early intervention to ensure positive long-term outcomes.

Twitter

Sponsors

Diamond Sponsor

  • AstraZeneca

 

Platinum Sponsor

  • Novo Nordisk

 

Platinum Sponsor

  • Novo Nordisk

 

Platinum Sponsor

  • Abbott

 

Gold Sponsor

  • GlucoRX

 

Gold Sponsor

  • Roche

 

Gold Sponsor

  • Insulet

 

Gold Sponsor

  • Lilly

 

Gold Sponsor

  • Napp Logo

 

Silver Sponsor

  • Sanofi

 

Silver Sponsor

  • CDEP

 

Silver Sponsor

  • glooko

 

Silver Sponsor

  • Aga Matrix

 

Silver Sponsor

  • Duet

 

Silver & Registration Sponsor

  • Diabetes Research & Wellness Foundation

 

Partners

Event Partner

  • NHS

Event Partner

  • ABCD

Event Partner

  • Diabetes Times

Event Partner

  • Trend

Event Partner

  • UKPCA

Media Partner

  • Caring Uk

Media Partner

  • Care Hub

Media Partner

  • Lifestyle Hub

Media Partner

  • Hospital Hub

Media Partner

  • Hub News

Media Partner

  • Practical Diabetes

Media Partner

  • Prescriber